#1 Clinical Trials Search in Europe

Nvl-655

Nvl-655, also known as Neladalkib, is an investigational drug currently being studied in clinical trials for patients with advanced ALK-positive non-small cell lung cancer (NSCLC) and other solid tumors. This article explores the ongoing research and potential benefits of Nvl-655 in treating these challenging conditions.

Table of Contents

What is NVL-655?

NVL-655 is a new medication being studied for the treatment of certain types of cancer. It is taken as an oral tablet, which means it can be swallowed as a pill[1]. This drug is specifically designed to target cancers that have a particular genetic change involving a protein called ALK (Anaplastic Lymphoma Kinase).

What Conditions Does NVL-655 Target?

NVL-655 is being investigated for the treatment of:

  • Advanced Non-Small Cell Lung Cancer (NSCLC) that has a specific genetic change called an ALK rearrangement
  • Other solid tumors that have either an ALK rearrangement or an activating ALK mutation
  • Locally advanced solid tumors (cancers that have spread from where they started to nearby tissue or lymph nodes)
  • Metastatic solid tumors (cancers that have spread to other parts of the body)[1]

How Does NVL-655 Work?

NVL-655 is what’s known as a selective ALK inhibitor. This means it’s designed to block the activity of the ALK protein when it’s abnormally active in cancer cells. By doing this, the drug aims to stop or slow down the growth and spread of cancer cells that depend on this protein to survive[1].

The ALKOVE-1 Clinical Trial

NVL-655 is currently being studied in a clinical trial called ALKOVE-1. This is a Phase 1/2 study, which means it’s in the early stages of testing in humans. The main goals of this study are to:

  1. Evaluate how safe NVL-655 is and how well patients tolerate it
  2. Determine the best dose to use in future studies
  3. See how effective it is at treating ALK-positive cancers[1]

Phases of the Clinical Trial

The ALKOVE-1 trial is divided into two main phases:

Phase 1

This phase focuses on finding the right dose of NVL-655. Researchers will:

  • Test different doses to see which is safest and most effective
  • Look for any side effects or dose-limiting toxicities (side effects that are severe enough to prevent increasing the dose)
  • Determine the recommended Phase 2 dose (RP2D), which is the dose they think will work best in the next phase of testing[1]

Phase 2

In this phase, researchers will use the dose determined in Phase 1 to:

  • Measure how well NVL-655 works in treating ALK-positive cancers
  • Continue to monitor for any side effects
  • Assess quality of life in patients taking the drug[1]

Patient Groups in the Study

The ALKOVE-1 trial includes several different groups of patients, each with specific characteristics:

  • Patients with NSCLC who have received one previous ALK-targeted therapy
  • Patients with NSCLC who have received 2-3 previous ALK-targeted therapies
  • Patients with NSCLC who have only received a drug called lorlatinib before
  • Patients with NSCLC who have never received an ALK-targeted therapy before
  • Patients with NSCLC who don’t fit into the other groups
  • Patients with other types of solid tumors that have ALK changes[1]

What the Study Aims to Measure

The ALKOVE-1 trial will look at several important outcomes, including:

  • Objective Response Rate (ORR): This measures how many patients’ tumors shrink or disappear after treatment
  • Duration of Response (DOR): How long the treatment keeps working
  • Progression-Free Survival (PFS): How long patients live without their cancer getting worse
  • Overall Survival (OS): How long patients live overall
  • Safety and side effects: What kind of side effects patients experience and how severe they are
  • Quality of life: How the treatment affects patients’ overall well-being[1]

Safety Considerations

As with any new medication, safety is a top priority in the ALKOVE-1 trial. Researchers will closely monitor patients for any side effects or adverse reactions. They will use a standardized system called CTCAE (Common Terminology Criteria for Adverse Events) to grade the severity of any side effects[1].

Potential Benefits of NVL-655

While it’s important to remember that NVL-655 is still in the early stages of testing, it has the potential to offer several benefits:

  • It may provide a new treatment option for patients whose cancer has become resistant to other ALK-targeted therapies
  • As an oral medication, it could be more convenient for patients than treatments that require hospital visits for infusions
  • It may be effective against a range of ALK-positive cancers, not just lung cancer
  • If successful, it could improve survival and quality of life for patients with ALK-positive cancers[1]

As the ALKOVE-1 trial progresses, more information will become available about the effectiveness and safety of NVL-655. Patients interested in this treatment should discuss it with their healthcare provider to determine if it might be an appropriate option for them.

Aspect Details
Drug Name Nvl-655 (Neladalkib)
Type of Drug Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor
Target Condition ALK-positive Non-Small Cell Lung Cancer (NSCLC) and other solid tumors
Administration Oral tablet
Clinical Trial Phases Phase 1/2 and Phase 3
Key Outcomes Measured Safety, Efficacy, Progression-Free Survival, Overall Survival, Objective Response Rate
Patient Populations Treatment-naive, previously treated with other ALK inhibitors, and those with limited treatment options
Comparator Drug Alectinib (in Phase 3 trial)

FAQ

  • What is Nvl-655 and what is it used for? Nvl-655, also known as Neladalkib, is an investigational drug being studied for the treatment of ALK-positive non-small cell lung cancer (NSCLC) and other solid tumors. It is a selective anaplastic lymphoma kinase (ALK) inhibitor designed to target specific genetic changes in cancer cells.
  • Who might benefit from Nvl-655 treatment? Patients with advanced ALK-positive NSCLC who have previously received other ALK inhibitors or have no satisfactory treatment options may benefit from Nvl-655. It is also being studied in patients with other solid tumors that have ALK rearrangements or mutations.
  • How is Nvl-655 administered? Nvl-655 is administered as an oral tablet taken daily. The exact dosage and frequency may vary depending on the specific clinical trial and patient needs.
  • What are the main goals of the Nvl-655 clinical trials? The main goals of the Nvl-655 clinical trials are to evaluate its safety, determine the appropriate dosage, and assess its effectiveness in treating ALK-positive NSCLC and other solid tumors. Researchers are measuring outcomes such as tumor response, progression-free survival, and overall survival.
  • Are there any side effects associated with Nvl-655? As with any investigational drug, the full range of side effects is still being studied. The clinical trials are closely monitoring for any treatment-emergent adverse events and changes in laboratory parameters to ensure patient safety and better understand the drug's effects.

Ongoing Clinical Trials on Nvl-655

  • Study comparing NVL-655 to alectinib in untreated patients with ALK-positive advanced non-small cell lung cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +7

  • Study of NVL-655 for Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with ALK Mutation

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Italy The Netherlands Spain

Glossary

  • ALK-positive: Refers to cancer cells that have a genetic change in the anaplastic lymphoma kinase (ALK) gene, which can contribute to cancer growth.
  • Non-Small Cell Lung Cancer (NSCLC): A type of lung cancer that is the most common form, accounting for about 80-85% of all lung cancers. It grows and spreads more slowly than small cell lung cancer.
  • Tyrosine Kinase Inhibitor (TKI): A type of targeted therapy that blocks specific enzymes called tyrosine kinases, which are involved in cancer cell growth and survival.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Duration of Response (DOR): The length of time that a tumor continues to respond to treatment without growing or spreading.
  • Overall Survival (OS): The length of time from the start of treatment that patients are still alive.
  • Blinded Independent Central Review (BICR): A method of assessing treatment outcomes where independent experts review patient data without knowing which treatment the patient received.
  • Quality of Life (QoL): A measure of a patient's overall well-being and ability to function in daily life during cancer treatment.

References